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Prionoid proteins are those proteins which can have different conformations, one of which can 
self-perpetuate and spread within an organism, but not between individuals. Traditionally, such 
proteins have been related to pathological conditions, such as various neurodegenerative 
diseases. Nonetheless, increasing evidence has been found that prionoid proteins may also 
perform functional roles when adopting the aggregated conformation, such as the ability to 
maintain long-term memory. However, the stimuli inducing the conformational switch of these 
proteins are still unknown, but various possibilities will be mentioned in this paper. Altogether, the 
study of pathological and functional prionoids is extremely important in order to understand their 
different aggregation process. Furthermore, acquiring a deeper knowledge may be of special 
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1. Introduction: What is a prion? 
The definition of Proteinaceous Infectious 
Particles (Prions) was initially proposed in 
1982 by Stanley Prusiner after the discovery 
of the Prion Protein (PrP), which is 
described as a protein capable of self-
replicating and forming persistent 
accumulations. The PrP is indeed 
responsible for causing transmissible 
spongiform encephalopathies, a set of 
neurogenerative disorders such as scrapie 
in animals and kuru or Creutzfeld-Jacob 
disease in humans. However, this definition 
has greatly expanded over the last years, 
as some prion characteristics are shared 
with other several proteins, broadening 
the concept of prion to prion-like 
proteins.1,2,3,4,5 
 
In the present project, further attention will 
be placed on prion-like proteins and their 
particular features in comparison to prions, 
in order to understand the differences 
between them. Furthermore, two prion-like 
proteins of the central nervous system 
(CNS), a-synuclein and CPEB, will be 
described due to their relevance for the 
mentioned tissue. Moreover, they provide 
an opposite perspective of prion-like 
proteins, useful for the proper 






Proteins are initially synthesized as linear 
chains of attached amino acids, which 
then fold into tridimensional or even more 
complex conformational structures (see 
Figure 1A). Sometimes, the different 
structures are obtained due to post-
translational modifications (PTM), such as 
SUMOylation or phosphorylation. Once 
these proteins have reached a specific 
structure, their particular functions are 
performed. Consequently, this allows a 
wide range of possible conformations for 
the very same protein, which can then 
lead not only to different functions but also 
to disease phenotypes.6,7 
 
Indeed, prions are able to self-template in 
a range of different conformations, each 
of one is called a strain. The strains, despite 
having the same polypeptide sequence, 
provide the proteins with distinct biological 
functions. In fact, these strains can arouse 
even without the aid of PTM, as the 
protein-only hypothesis supports,2,6 which 
suggests that such flexibility in protein 
conformation is regulated exclusively by 
the primary amino acid sequence of the 
prion. 
 
The most common structure adopted by 
prions is the amyloid form, which consists of 
an aggregation of b-sheet rich fibrils 
(Figure 1B). Usually, as in the PrP protein, 
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there is a conformational misfolding in 
which the proteins turn from a majoritarian 
a-helix conformation into a b-sheet 
structure.  Therefore, while the first 
conformation was functional, the 
transformation into the amyloid structure 
causes the persistent aggregation of 
dysfunctional proteins, leading to disease. 
Such aggregation has been proposed to 
spread due to a seeded nucleation 
process, a mechanism that involves a first 
switch of a protein to a b-sheet structure, 
which would then act as a seed and 
trigger the same conversion in other 
correctly folded monomers of the same 
protein. Then, a progressive growth of the 
aggregate happens while the b-sheet 
regions of the newly misfolded proteins 
interact among them (Figure 1B). 
However, it is important to remark that not 
all amyloids act as prions, although most 
prions are amyloidogenic proteins.8,9,10  
 
In terms of primary structure, most prions 
have flexible intrinsic disordered regions 
(IDR), which are regions that do not adopt 
a specific tertiary structure. Therefore, IDRs 
are in part responsible for the 
characteristic conformational flexibility of 
prions. Sometimes, prions can be 
intrinsically disordered proteins, which 
implies that the whole protein is disordered 
and, in consequence, does not form 
amyloids either.6,7,11  
Figure 1. Process of formation of a prion or prion-like protein.  A) Formation of a protein with different strains, 
with and without post-translational modifications (PTM). B) Formation of an amyloid structure and its spread 




Two other regions are also commonly 
found in prions. First, the compositionally 
biased regions (CBR), which means that a 
concrete region has a different proportion 
of residues than the expected by the 
average. Second, the low complexity 
regions (LCR), which refers to those regions 
with an enrichment in certain amino acids. 
In this case, prions usually have either N-
/Q- enriched regions or hydrophobic rich 
domains. These regions have been 
suggested to be involved in the already 
mentioned conformational switch, as they 
allow the change to a b-strand 
conformation and, therefore, the 
formation and aggregation of the amyloid 
form. However, if these N/Q-rich regions 
are not present, IDR sequences can 
induce the aggregation in the same way. 
Besides, N-/Q- rich domains may also be 
important in DNA and RNA-binding or in 
protein interactions. 8,12  
 
Nonetheless, some of the newly identified 
prions in bacteria and fungi neither had 
CBR regions nor formed amyloid structures, 
although they shared IDR.6 Accordingly, it 
is important to consider all the structural 
features above mentioned, and not only 
the capacity of forming amyloids, for the 




The most striking characteristic of prions is 
their ability to spread through cells, tissues 
and, most important, between individuals. 
Thus, prions are considered infectious, as 
they are capable of invading and self-
perpetuating in a susceptible host, 
regardless whether they cause disease or 
not. 10,13 
 
Prions’ capacity of spreading is related to 
the already mentioned seeded nucleation 
mechanism coupled with the ability of 
prions to overcome proteostasis processes, 
so the aberrant forms cannot be 
deleted.6,14 In consequence, as prion 
aggregates are constantly growing, they 
are susceptible to fragmentation. Then, if 
those fragments are transported to other 
cells, they can act again as seeds and 
induce the oligomerization of inner 
monomers, provoking the cells’ 
infection.8,13,15 Nonetheless, the infection 
would only propagate if the recipient host 
(say, cell, tissue or individual) also 
expresses the precursor of the prion 
protein.6,10 Remarkably, this transmission is 
independent of nucleic acids, which was 
an unprecedented discovery.13 
 
To summarize, the basic features of prions 
are their ability to self-propagate, say, 
trigger their own change to an 
aggregated form; and also the capacity 
of spreading within susceptible hosts.  
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2. Prionoid proteins 
2.1. Introduction 
Prionoid proteins (prionoids from now on), 
also called prion-like proteins, are proteins 
which, despite sharing some of the prions’ 
structural features and their spreading 
capacity and mechanism, are not 
transmissible between individuals. 
Nonetheless, prionoids can be confined in 
the cell in which they appear or can 
migrate within cells or tissues.6,10,12,13 Various 
disease-related proteins can be included 
in this definition, such as a-synuclein and 
amyloid b, whose amyloidogenic form is 
related to Parkinson and Alzheimer disease 
respectively.8,16   
 
Moreover, recent studies suggest that 
prionoid proteins are more common than 
originally thought, as various proteins with 
regulated, physiological functions have 
been discovered to share prions’ 
properties. Thus, those proteins which  
 
acquire or change their function once the 
aggregated state is achieved are known 
as functional prionoids. Currently, the 
knowledge of functional prionoids is 
scarce but constantly raising, being all of 
them involved in cell-regulated functions, 
in stark contrast to the unregulated, 
irreversible oligomerization related to 
prions and pathological prionoids.16,17 In 
Table 1, examples of both disease-related 
and functional prionoids in the animal 
kingdom are mentioned, although in the 
present project the focus of attention will 
be over a-synuclein and CPEB.  
 
2.2. a-synuclein: Parkinson’s Disease 
2.2.1. Epidemiology 
An example in which prionoids are 
involved in are synucleopathies. One of 
the most prevalent synucleopathies is 
Parkinson’s Disease (PD), which has had an 
increasing prevalence over the last years, 
affecting 1% of the population over 60 
Disease-related prionoid14 Functional prionoid 
Amyloid b14 Alzheimer’s disease CPEB18 
Long term memory 
maintenance 
a-synuclein14 Parkinson’s disease MAVS19 
Immunological 
system 




p53 21 Cancer RIP1/RIP3 complex22 
TNF-induced 
programmed necrosis 
Table 1. Examples of both disease and functional prionoids. In the left column, the name of the protein is 
written. In the right, the process or disease related to the prionoid form of the protein. 
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years. Therefore, PD is the second more 
common neurodegenerative disease, 
after Alzheimer’s. Although the majority of 
PD cases are idiopathic, there is an 
important genetic risk, mostly induced by 
sporadic causes. However, around 10% of 
these genetic cases are familiar forms, 
usually involving mutations in the a-
synuclein coding gene, SNCA. One of the 
most common hereditary forms of PD, in 
fact, is the SNCA missense mutation A53T. 
13,23,24,25,26  
 
2.2.2. Characteristics of a-synuclein 
The a-synuclein protein is part of the 
synuclein family, together with b and g-
synuclein. The a-synuclein form has 140 
amino acids and it is highly expressed in 
the brain, although it can also be found in 
other tissues. However, its biological 
function has not been determined yet. 
Otherwise, this protein shows a tendency 
of forming oligomers in vivo, so when 
monomers turn to a b-sheet conformation, 
they form insoluble, neurotoxic fibrils, 
similarly to prions.27  
 
Accordingly, it would be logical to look for 
some of the already mentioned prions’ 
characteristics in the structure of a-
synuclein. Indeed, there are similarities, as 
a-synuclein has a central CBR, formed by 
12 hydrophobic amino acids, which is 
essential for its oligomerization.23    
2.2.3. Pathology 
The typical hallmark of PD are Lewy 
bodies, caused by the accumulation of a-
synuclein. When analyzing Lewy bodies, 
90% of the a-synuclein forming such 
aggregates was discovered to be 
phosphorylated on its serine 129, so this 
raised the question if PTM may play a role 
in the oligomerization process. However, 
Karampetsou et al.28 demonstrated that, 
although the phosphorylation of a-
synuclein accelerates the pathology, it is 
not essential for the formation of oligomers 
(Figure 2). Nonetheless, the effect of such 
phosphorylation is critical for PD, as it: 
- Increases the aggregation capacity of 
a-synuclein. 
 
- Reduces the innate immune system 
response, diminishing macrophages 
infiltration and modifying the 
production of certain cytokines, such as 
TNFa and IL-10. 
 
- Induces a higher uptake of extracellular 
a-synuclein by neurons. 
 
Moreover, aggregated a-synuclein has 
been suggested to spread within healthy 
neurons, especially among those which 
form neural circuits. Such neurons are in 
tight contact, so the aberrant form of a-
synuclein is transmitted both by exocytosis 
and endocytosis. Another point to bear in 
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mind is that, after some time, neurons 
affected by a-synuclein aggregation may 
die and the aggregates would then be 
released to the medium, being susceptible 
of reuptake by nearby cells. Under these 
circumstances, the seeded-nucleation 
mechanism is also applicable, as after the 
first oligomer is endocytated it would 
cause the aggregation of endogenous a-
synuclein too (Figure 2).13,27,29  Furthermore, 
this is consistent with the Braak hypothesis, 
which suggests that the progression of PD 
takes place within neural circuits and 
expands progressively to further regions, 
mainly affecting dopaminergic 
neurons.13,16,30 Nonetheless, if the target 
areas do not express the a-synuclein 
protein, as demonstrated with exogenous 
injections of a-synuclein in null a-synuclein 
mice, the aggregates are unable to 
form.13,28,29 
  
In fact, a-synuclein aggregates have a 
great potential of spreading, as various 
studies suggest. On the one hand, it was 
demonstrated by intraglosally and 
intraperitoneal a-synuclein injections that 
an invasion of the whole nervous system, 
including the spinal cord, happens even 
after a distal administration.24 On the other 
hand, if a-synuclein is injected in certain 
areas of the brain, the aggregates spread 
throughout the CNS, even to the 
contralateral side of the injection,28,29 
which seems controversial to Braak 
hypothesis as these areas are not 
Figure 2. Different factors involved in PD pathology. On the top, the misfolded form of a-synuclein appears 
after an unknown stimulus. Then, the external A53T form present in food and the Ser-129 phosphorylated a-
synuclein may also participate in further aggregation. Finally, both neurons endocytosis and astrocytes 
transport of aggregated a-synuclein participate in spreading the pathology throughout the brain. Figure 
designed by the author. 
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interconnected. A hypothesis that may 
explain this wide, fast spread of the 
pathology is that aggregates could be 
“transported” by some cellular 
components, such as astrocytes (Figure 2). 
Indeed, astrocytes engulf a-synuclein in 
order to degrade it, but instead they could 
act as a vehicle and transport the prionoid 
to other regions, even to unconnected 
ones.29,31 
 
Despite all the experiments mentioned 
until here were carried using external 
injections of a-synuclein, neither the origin 
of the disease itself nor what triggers the 
transformation of the protein has been 
determined yet. Nevertheless, a recent 
paper has suggested a possible source of 
income of a-synuclein for humans: food. 
This fact is consistent with the experiments 
above mentioned, as human a-synuclein is 
able to aggregate in mice31,32 and 
misfolded human a-synuclein is also 
capable of triggering the pathogenic 
process in primates,33 despite some 
differences in the sequence. Then, taking 
into account that the mutated A53T a-
synuclein seems to be present in meat 
products, food could be a potential 
source of aberrant a-synuclein. A53T, in 
fact, has already been mentioned for its 
ease of aggregation in the familiar form of 
PD (Figure 2). Accordingly, these ingested 
forms could seed in the human gut, as 
seen in Figure 3, and then spread through 
the vagal nerve until the CNS. 
Nonetheless, many other risk factors like 
genetic predisposition or inflammation 
Figure 3. Vertebrate species ingestion can be a source of prionoid a-synuclein. The ingested form can seed 
in the lumen and infect enteric neurons. Hence, prionoid forms would be able to propagate until the CNS 
via the vagal nerve. Modified of Killinger et al.27 
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diseases could interfere with dietary 
factors to induce PD, so the ingestion of 
aberrant a-synuclein per se is not the 
cause of the disease. However, there are 
groups which totally discard this hypothesis 
due to lack of solid evidence.27,29 All in all, 
although misfolded a-synuclein ingestion 
seem to be a plausible cause of PD in 
humans, further studies should be 
performed in this area.  
 
2.3. CPEB 
2.3.1. The role of CPEB in Long-Term 
Memory 
Long-Term Memory (LTM) comprehension 
is of vital importance to understand the 
essential role of CPEB. Memory can be 
divided in two types: short-term memory, 
which is retained from seconds to minutes; 
and long-term memory, which can last 
from days, weeks or for a lifetime. Then, 
LTM relies on long-lasting changes in gene 
expression, which would then cause a 
structural and functional plasticity 
adaptation in synapses. But, taking into 
account that proteins have relatively short 
half-lives due to cell natural turnover, how 
can synaptic changes last for such a long 
amount of time? 
 
Changes in gene expression can happen 
at different levels, although two phases 
are of great importance for the present 
purpose: new genes transcription, for 
which activation of transcription in the cell 
nucleus is necessary; and translation of 
dormant mRNA, which happens locally in 
the activated synapses. Already in 1998, 
Tompa and Friedrich announced the 
“prion theory of memory”,34 stating that 
LTM maintenance could be dependent on 
prion proteins, due to their self-sustained 
and persistent state. Although the first 
process is out of the scope of this project, 
CPEB protein has been proposed as a 
regulator of mRNAs translation, inducing it 
when adopting the functional prionoid 
conformation.12,34,35,36 
Figure 4. A) In a basal state, CPEB protein forms monomers which can bind certain mRNAs, avoiding their 
translation by inhibiting their polyadenilation (dormant mRNA). In response to a specific stimulus, CPEB 
conformation changes and B) adopts a fiber structure, with the prion domain (PRD) forming the core fiber and 
the RNA-binding domain (RBD) being exposed to the cytoplasm. RBDs can then anchor target mRNAs and 





CPEB corresponds to Cytoplasmic 
Polyadenilation Element Binding protein, 
which means that CPEB binds the 3’ UTR 
CPE region of certain mRNAs in order to 
induce their polyadenylation and 
subsequent translation. The neuronal 
isoform of CPEB is confined to synapses, 
where it acts as a repressor of certain 
mRNA in the basal, monomeric state 
(Figure 4A).34 However, after a concrete, 
specie-dependent signal, local CPEB is 
activated and turns into its self-sustained, 
multimeric form, inducing then the 
translation of bound mRNAs (Figure 4B). 
With this mechanism, several targets can 
be translated at the same time in the 
specific location where they are needed, 
inducing long-lasting synaptic 
changes.12,17,36,37 Accordingly, CPEB 
activation should exclusively happen in 
the synapses where the synaptic 
modulation is necessary. Hence, the CPEB 
fiber must be retained in the stimulated 
region, without spreading neither between 
neurons nor synapses.3,36  
 
Different forms of CPEB protein exist, 
although in the present project only three 
types will be mentioned: Aplysia CPEB, 
Drosophila Orb2 and mammalian CPEB3. 
Despite all of them share the same 
function; their regulation, mechanism of 
action and targets are different 
depending on the studied specie, as 
detailed below. 
Various experiments have been 
performed in order to prove the 
importance of CPEB in LTM. Among all of 
them, the behavioral test based on 
courtship conditioning in Drosophila 
melanogaster is one of the most recurrent, 
as it shows that a male exposed to a non-
receptive female acquires the capacity of 
discriminating between unreceptive and 
receptive females. Therefore, normal 
trained males develop LTM and can 
“remember” when to perform or suppress 
the courtship activity, depending on the 
type of female. In Drosophila Orb2 
mutants, which cannot form the prionoid 
aggregation, memory was lost 9 hours 
after the first training (Figure 5), 
demonstrating the importance of CPEB for 
LTM.38 Otherwise, if CPEB aggregation is 
prevented by adding a specific antibody 
against it, LTM would not be stabilized 
more than 72 hours.36 
Figure 5. According to courtship conditioning 
studies, memory is lost beyond 9 hours in 
Drosophila Orb2 mutants (red line) in 
comparison to wild type (blue line).  





2.3.2. Aplysia CPEB 
The first discovered CPEB, Aplysia CPEB 
(ApCPEB), has a 48% Q/P-rich region in its 
N-terminal domain, a C-terminal region 
with a RNA-binding domain and some 
coiled-coil helices between them (Figure 
6A).35,39  
 
In this case, the coiled-coil helices have 
been suggested to regulate the 
oligomerization of this protein, as they are 
accessible to environmental regulations, in 
sharp contrast to pathological 
prionoids.3,35,37,39 Specifically, serotonin (5-
HT) synaptic stimulation is the signal which 
induces ApCPEB switch to a b-sheet-
enriched amyloid structure.35,36 Then, as 
seen in Figure 7A, ApCPEB forms a fiber 
structure and binds its target mRNAs. In this 
point, ApCPEB facilitates the 
polyadenylation of several mRNAs at the 
same time, allowing a rapid increase in the 
LTM-related proteins concentration.35  
 
The mechanism by which 5-HT induces the 
oligomerization of CPEB was unknown until 
2015, when it was proposed that 5-HT 
signal downregulates certain miRNAs, such 
as miR-22 and miR-124, both expressed in 
the nervous system. In fact, miR-22 induces 
the degradation of ApCPEB mRNA by 
binding its 3’ UTR region, as shown in Figure 
6B. Accordingly, the inhibition of miR-22 
results in an increase of ApCPEB 
concentration, allowing its aggregation in 
the multimeric, active form.40 Indeed, this 
was the first evidence that 5-HT controls a 
whole set of non-coding RNAs, which at 
the same time regulate the translation of 
LTM-related proteins. However, more 
mechanisms could also be involved in 
ApCPEB activation.  
 
ApCPEB reversible multimerization is 
another important difference in 
comparison to pathological prionoids, 
again probably by the coiled-coil helices. 
Such helices are not included in the fiber 
axis and, hence, are accessible even in 
the multimeric conformation.35 
Furthermore, it has been proposed that 
heat-shock proteins like HSP104 are able to 
remodel and reverse the active state of 
ApCPEB to its basal conformation, 
allowing the de-potentiation of synapses.36  
Figure 6. Schematic representation of the neuronal 
isoform of Aplysia CPEB. A) Structure of Aplysia CPEB, 
where the red is the prion domain and the blue, the 
RNA-binding domain.35 B) Scheme of miR-22 binding 
to the 3’ UTR region of ApCPEB mRNA. Red lines 
indicate possible binding sites. The homology of the 
sequence regarding the first homologous segment is 





2.3.3. Drosophila Orb2 
Drosophila homologue of ApCPEB is called 
Orb2, member of the CPEB2 family, which 
has two different isoforms: Orb2A and 
Orb2B. These isoforms, although they differ 
in the composition before the prion 
domain, also share a Q-rich region in the 
N-terminal domain; while in the C-terminal 
region a RNA recognition motif and a zinc 
finger are found. Therefore, Orb2 also 
regulates local mRNA translation.38,41,42  
 
However, certain differences between 
ApCPEB and Orb2 can be found. Firstly, it 
is worth to mention that the multimerization 
of Orb2 is regulated in response to 
octopamine, dopamine or tyramine, not 
by serotonin.41,43  Secondly, it seems that 
Orb2A, whose concentration is low and 
specially localized in synapses, is the form 
which induces the oligomerization of 
Orb2B, while this one is widely distributed 
and binds strongly to target mRNAs.3,41,42 In 
third place, Orb2 activation depends on its 
phosphorylation by Tob-LimK complex in 
response to tyramine, which stabilizes the 
protein concentration of Orb2A and then 
triggers its seeded nucleation.43  
 
Furthermore, although the N-terminal 
domain of Orb2A is essential for the 
formation of the fiber core, its Q-rich region 
is excluded of it. In fact, such region has 
been proposed as a stabilizer or regulator 
of the multimeric form, but its function is still 
elusive. On the opposite, Orb2B is 
indispensable for RNA binding, so both 
Orb2 forms have complementary 
functions (Figure 7B).41,44  
 
Recently, another regulatory point has 
been suggested for Orb2, as it seems that 
the amyloid formation is also dependent 
on the latter part of the N-terminal 
domain, which has metal binding 
capacities. Orb2 oligomerization, indeed, 
is increased in presence of several metals, 
which suggest that not only 
neurotransmissors but also metals, such as 
Zn2+ -whose concentration increases 
during memory processes-, may induce 
the prionoid change in Orb2 proteins.45   
 
2.3.4. Mammalian CPEB3 
Although four CPEB forms have been 
described in vertebrates, only CPEB3 can 
be considered an homologous of ApCPEB, 
as it also presents the two different states 
and performs the same biological 
function. Accordingly, such form has been 
extensively studied in mice, even though it 
is also present in humans.46 
 
The particular regulation of CPEB3 implies 
such protein being SUMOylated in its basal 
state; while its monoubiquitination, which 
increases after synaptic stimulation, leads 
to its aggregation. Moreover, as seen in 
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Figure 7C, the switch between basal and 
active conformations is promoted by 
dopamine, glutamate and glycine.12,47,48,49 
However, if further modifications or 
processes are involved in this regulation or 
how CPEB3 returns to its basal state is still to 
be discovered.49 
 
Furthermore, the prion domain of CPEB3 
has three different parts: a PRD1, which 
contains the Q/N-rich domain, a PRD2 and 
an in-between regulatory region. Such 
regulatory domain, in fact, interacts with 
actin filaments when adopting the 
prionoid form (Figure 7C). Through this 
interaction, CPEB3 is concentrated in 
certain synaptic regions and, hence, its 
aggregation rate is increased.46 
3. Discussion  
As a consequence of broadening the 
concept of prions, the discovery of 
prionoid proteins has been possible, whose 
transmission is restricted within individuals 
and can be both pathological or 
functional. This is an important point to 
consider when differentiating prions and 
prionoids, as despite both can be 
infectious, only prionoids may perform 
signal-regulated biological functions in the 
amyloid form. Such functional prionoids, 
although already proven in yeast, are a 
recent discovery in eukaryotic organisms.6 
 
One of the most important disease-related 
prionoids is a-synuclein, which causes PD. 
However, the severe and fast outcome of 
Figure 7. Differences among specie-specific CPEBs. A) If ApCPEB is bound to miR-22, it is degraded. On the contrary, 
under serotonin stimulus, miR-22 is degraded and ApCPEB concentration increases, inducing its aggregation in the 
amyloidogenic form. Then, certain targets are translated, such as CamKII34 and actin37. B) In response to extracellular 
signaling, the Tob-LimK complex is activated. Consequently, Orb2A is phosphorylated and stabilized. Hence, Orb2A 
forms the core of the fiber axis, initiating the seeded nucleation process and recruiting Orb2B monomers. Otherwise, 
exposition to certain metals can also induce the same conformational change. In this case, different targets are 
translated, like Tequila42. C) CPEB3 is SUMOylated in its basal state. Under specific stimuli, the SUMO group is exchanged 
for a monoubiquitin. Such monoubiquitination induces CPEB3 aggregation and the translation of targets such as GluR1-
GluR2 (subunits of AMPA receptor) and actin.46 Furthermore, the oligomeric form of CPEB3 is transported to specific 
regions due to its interaction with actin filaments. Figure designed by the author.  
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PD is the consequence of a combination 
of various factors. First, the phosphorylation 
of a-synuclein, which enhances its 
aggregation. Secondly, the possibility that 
astrocytes and other cells may act as 
transporters of the pathological form 
within the brain, although further 
investigation should be performed in this 
field. Accordingly, the amyloid 
conformation does not cause the 
pathology exclusively by itself, but it 
requires its combination with other factors. 
This is also related to the fact that the 
ingestion of misfolded forms of a-synuclein 
seem to trigger PD in human beings, but 
solid evidence is still missing. Besides, 
available treatments for PD are quite 
inefficient, with several side effects and 
poor results, as they do not treat the real 
focus of the pathology.50 Hence, should it 
be considered that Parkinson’s Disease is 
not being addressed with the most suitable 
strategy? 
 
Another important protein in the CNS is 
CPEB, both in its monomeric and 
oligomeric form, which is essential for LTM. 
Despite certain peculiarities in each 
specie, this functional prionoid is always 
related to synaptic plasticity.  This fact also 
suggests that functional prionoids have 
been conserved along evolution. Then, 
their deeper study may not only provide 
further comprehension of various 
biological functions but also help in the 
development of suitable treatments for 
pathological prionoids.  
 
To summarize, prionoid proteins are far 
more common than previously thought, 
and their wide comprehension is of vital 
importance both for pathological and 
physiological conditions.  By studying 
them, it could be possible to discover: 
 
1. Which events trigger the pathological 
prionoids formation and identify which 
processes are involved in their 
expansion, in order to manipulate 
them and avoid neurodegenerative 
diseases. 
 
2. Whether the artificial recruitment of 
functional prionoids could anyway 
induce their biological function as, for 
example, for stabilizing memories 
when treating memory deficiency 
diseases.  
4. Conclusions 
Hitherto, the main facts related to both 
functional and pathological prionoids 
have been exposed. As a result, 
conclusions are: 
- Prions and prionoids share the main 
structural characteristics and the 
spreading mechanism, despite the 
latter not being transmissible between 
individuals. 
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- Prionoid proteins can be both 
pathological or functional. As opposite 
to pathological prionoids, functional 
ones are regulated by cell and 
environmental signaling. Furthermore, 
functional prionoids’ aggregation can 
be reversed. 
 
- The disease-related prionoid a-
synuclein reaches a severe 
pathological state due to the 
combination of its aggregation with 
other processes. 
 
- The functional prionoid CPEB plays an 
important role in LTM, a conserved 
function along species. However, its 
regulation and targets may differ 
among the different homologous 
proteins of each specie. 
 
- Prionoids' deep study could be 
extremely useful for the development of 
new treatments, such as in: 
o Treating neurodegenerative 
diseases in a more efficient manner. 
For example, treating PD by 
avoiding amyloid formation may be 
also interfering in functional 
prionoids’ aggregation.  
 
o Treating memory deficiency 
diseases by exogenously triggering 
the oligomerization of functional 
prionoids, like CPEB. 
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